Docoh
Loading...

Fri. 5 Nov 2021, 9:51am ETBenzinga
In: News, Price Target, Analyst Ratings
Stephens & Co. analyst Jacob Johnson maintains NeoGenomics (NASDAQ:NEO) with a Overweight and lowers the price target from $60 to $53.